theMednetRegister

Stage III NSCLC   

Questions discussed in this category

Do you stop consolidative durvalumab after one year as per the PACIFIC trial or continue if the patient is otherwise tolerating well?
1 Answer available
Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?
One particular circumstance involved detecting a ROS1 fusion upon the metastatic recurrence.  Is this pneumonitis risk seen with osimertinib alon...
2 Answers available
Do you consider NSCLC with multistation N2 involvement appropriate for treatment with neoadjuvant chemoimmunotherapy followed by surgery?
6 Answers available
Are there situations in which neoadjuvant chemoimmunotherapy + surgery would be preferred over chemoradiation + consolidative immunotherapy for stage III lung cancer?
1 Answer available
How do you choose between neoadjuvant chemotherapy alone vs neoadjuvant chemoradiation in patients with potentially resectable stage III NSCLC who are not upfront surgical candidates?
1 Answer available
For which patients with resected NSCLC will you offer adjuvant atezolizumab after completion of cisplatin-based adjuvant chemotherapy?
Will degree of PD-L1 status impact your decision? Would you ever offer to stage IB patients as per study enrollment?  Do AJCC v8 staging guideli...
4 Answers available
How do you approach patients with Stage IIIB/C NSCLC with ipsilateral supraclavicular (N3) disease?
Do you initially start with systemic therapy alone or do you proceed directly to chemo-radiation? 
1 Answer available
What would you offer as adjuvant therapy for a resected stage IIIB adeno NSCLC in a patient who refuses chemotherapy?
Can adjuvant durvalumab or other I/O or osimertinib (if EGFR+) be considered?
2 Answers available
How do you approach missed doses of durvalumab consolidation in patients with Stage III NSCLC?
Do you aim to give a total of 26 doses or do you stop at one year from first dose no matter how many were given?
1 Answer available
Would you consider maintenance immunotherapy following chemoradiation for a patient with an isolated mediastinal recurrence of NSCLC?
1 Answer available
How do you manage pneumonitis in patients with Stage III NSCLC receiving durvalumab?
How do you prescribe a steroid taper? If it is grade 2, would you keep them on low dose prednisone while continuing? When do you feel comfortable re-c...
2 Answers available
How do you approach elderly patients with stage III NSCLC who have a reasonable performance status?
Do you recommend or make any modifications in the PACIFIC regimen for patients > 75 years of age?
1 Answer available
How do you monitor response for stage III NSCLC patients receiving consolidation immunotherapy?
CT or PET? If so, how often?
3 Answers available
How do you time re-staging studies and adjuvant durvalumab for stage III NSCLC treated with definitive cCRT?
Do you feel it is important to start durvalumab within 14 days of completing cCRT?  What real life challenges do you face in doing so and wh...
1 Answer available
Do you recommend adjustment of lung dose constraints in the setting of stage III lung cancer treated with definitive concurrent chemoradiation followed by planned consolidation immunotherapy?
3 Answers available


Papers discussed in this category

Lancet (London, England), 2009-08-01
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
Lung Cancer,
Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature.
Lancet Oncol., 2008 Jun 24
Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer.
The New England journal of medicine, 2018-12-13
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
JAMA oncology, 2019-07-01
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
N Engl J Med, 2017 Nov 16
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
N Engl J Med, 2020 Sep 19
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.
Lancet (London, England), 2019-05-04
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
J Clin Oncol, 2021 Apr 19
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
Lancet, 2021 Sep 20
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
The Lancet. Oncology, 2015-02
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
J. Clin. Oncol., 2015 Nov 02
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
N Engl J Med, 2022 Apr 11
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Eur Respir J, 2005 Aug
Morbidity and mortality in the surgery arm of EORTC 08941 trial.
N Engl J Med, 2023 Jun 28
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
The New England journal of medicine, 2018 Apr 16
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
The Lancet. Oncology, 2020 May 07
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Translational lung cancer research, 2019 Sep
Pathologic response after modern radiotherapy for non-small cell lung cancer.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2009 Aug 21
Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection.
Cancers, 2021 Sep 26
Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy.
Clinical lung cancer, 2023 Jul 25
Effect of Surgical Treatment for N2-Positive c-stage III Non-Small Cell Lung Carcinoma in the "PACIFIC" Era.
ERJ open research, 2020 Feb 17
International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?
Clinical Medicine Insights. Oncology, 2023 Feb 14
Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer.
J Thorac Oncol, 2018 Mar 06
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
JTO clinical and research reports, 2022 Jun 25
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced -Positive NSCLC.

Related Topics

Copyright © 2025 theMednet
All Rights Reserved.